Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune
Alvopetro Announces Q3 2026 Financial Results and an Operational Update Including 183-G2 Well Results